Previously submitted to: JMIR Medical Informatics (no longer under consideration since Jun 22, 2021)
Date Submitted: Mar 5, 2020
Radiofrequency Ablation Guided by CartoUnivu and Carto3 Intelligent Systems for the Treatment of Tachyarrhythmia: Randomized Controlled Trial
Background:
Radiofrequency ablation has obvious advantages in the treatment of arrhythmia, like few postoperative complications, high cure rate, low recurrence rate, and low trauma, and it has become the first choice to treat patients with arrhythmia.
Objective:
This paper aims to determine the x-ray dose associated with radiofrequency ablation, guided by the CartoUnivu (Biosense Webster Inc) and Carto3 (Biosense Webster Inc) intelligent systems in patients with paroxysmal supraventricular tachycardia (PSVT) and patients with premature ventricular contractions (PVC) and ventricular tachycardia (VT) arrhythmia.
Methods:
Radiofrequency ablation guided by the CartoUnivu and Carto3 systems was used to treat patients with PSVT and patients with PVC and VT arrhythmia, and the x-ray doses delivered to the thyroid, perineum, left upper arm, intrathyroid, extrathyroid, intrathoracic region, extrathoracic region, intraperineum, extraperineum, and other parts of the body during the treatment were analyzed.
Results:
In most patients with PSVT, radiofrequency ablation guided by the Carto3 system had a lower x-ray dose than that of CartoUnivu. Radiofrequency ablation under the guidance of the CartoUnivu system resulted in lower x-ray radiation for patients with PVC and VT.
Conclusions:
The CartoUnivu and Carto3 systems can guide the precise treatment of complex arrhythmia, have a high success rate and good safety, reduce the x-ray exposure time and dose received by patients and operators, and reduce the risk of x-ray–related damage and are therefore worth promoting.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.